Ratings 4D Molecular Therapeutics, Inc.

Equities

FDMT

US35104E1001

Market Closed - Nasdaq Other stock markets 02:00:01 04/05/2024 am IST			5-day change	1st Jan Change
26.38 ^USD	0.00%		+13.46%	+30.21%

15/04	Barclays Starts 4D Molecular Therapeutics With Overweight Rating, $45 Price Target	MT
15/04	RBC Raises Price Target on 4D Molecular Therapeutics to $40 From $35, Keeps Outperform Rating, Speculative Risk Qualifier	MT

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental situation
The company has a poor ESG score according to Refinitiv, which ranks companies by sector.

Strengths

Thanks to a sound financial situation, the firm has significant leeway for investment.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Over the past four months, analysts' average price target has been revised upwards significantly.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
Based on current prices, the company has particularly high valuation levels.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
4D MOLECULAR THERAPEUTICS, INC.	+30.21%	1.35B	C-
MODERNA, INC.	+25.69%	47.86B	B-
LONZA GROUP AG	+46.90%	41.42B	A
IQVIA HOLDINGS INC.	-3.46%	40.66B	B
CELLTRION, INC.	-6.20%	28.92B	C
ICON PUBLIC LIMITED COMPANY	+9.17%	25.55B	B-
ALNYLAM PHARMACEUTICALS, INC.	-20.42%	19.27B	B
MEDPACE HOLDINGS, INC.	+28.07%	12.14B	C+
BIO-TECHNE CORPORATION	+0.17%	12.15B	B+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.24%	11.99B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes